New Developments in the Diagnosis and Management of Chronic Obstructive Pulmonary Disease
Released On
March 1, 2024
Expires On
March 1, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology, Pulmonology
Topics
COPD
This activity is provided by Med Learning Group and AMEDCO.
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by an independent medical education grant from AstraZeneca Pharmaceuticals, and Daiichi Sankyo.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Nursing contact hours
Nursing learners, view this Learner Notification prior to starting this activity.
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is specifically designed for US-based pulmonologists and respiratory therapists involved in the diagnosis and management of patients with COPD.
Program Overview
This enduring HoloVision™ activity is an online program designed to advance the abilities of US-based pulmonologists and respiratory therapists and provide the tools to determine an accurate diagnosis of COPD using new diagnostic methods; understand how interleukin (IL)-4/13 and IL-33 signaling pathways affect the pathophysiology of COPD; and review data from clinical studies of the clinical profiles of new and emerging treatments for COPD.
Learning Objectives
- Facilitate a timely and accurate diagnosis of COPD using novel diagnostic methods
- Evaluate the roles of the interleukin (IL)-4/13 and IL-33 signaling pathways in the pathophysiology of COPD
- Assess data from studies investigating the clinical profiles of emerging therapies for the treatment of COPD
Faculty
Nicola A. Hanania, MD, MS, FCCP, FACP, FRCP(C), FERS
Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief, Section of Pulmonary and Critical Care Medicine
Ben Taub Hospital
Houston, Texas
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
In suppport of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosures of Conflicts Of Interest
- Nicola A. Hanania, MD
- Consulting Fees: AstraZeneca, GSK, Boehringer Ingelheim, Sanofi/Regeneron, and Genentech
- Research and Grant Funding: National Heart, Lung, and Blood Institute (NHLBI), American Lung Association (ALA), GSK, Boehringer Ingelheim, AstraZeneca, Genentech, and Sanofi
Instructions for Participation and Credit
TThere are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Contact Information
For CME questions please contact Med Learning Group at: [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.